News

There was no statistically significant difference between treatment-related adverse events in the SB623 stem cell and control groups.

The follow-up TRAILBLAZER-EXT and broader population TRAILBLAZER-ALZ 2 studies are currently ongoing.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the future outlook of ezogabine and whether it may be studied again in patients with ALS.

Episode 5 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Steven Vernino, MD, PhD, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]

Research led by movement disorders specialist Un Jung Kang, MD, searches for clues to help diagnose and treat Parkinson’s disease in its earliest stages, well before symptom onset.

The percentage of women who had ≥1 change in an antiepileptic drug dose or an overall dose increase during pregnancy and a decrease in dose during the postpartum period was higher among pregnant women than controls.

Here's what is coming soon to NeurologyLive.

The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.

MR imaging revealed minimal fat infiltration in the SRP-9001 arm compared to participants with DMD from the natural history cohort.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.

Although the percentage of total seizures arising from REM was low, it is notable that 2 out of 26 patients (7.7%) had REM-onset seizures.

Neurology News Network for the week ending January 9, 2021.

Health care professionals and a caregiver discuss the overall burden of hallucinations and delusions associated with dementia-related psychosis, explore unmet needs in diagnosis and management of these symptoms, and discuss the need for increased dialogue between clinicians and caregivers.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

The investigation identified 13 novel and significant associations with cerebrovascular disease and transient cerebral ischemia.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The Expanded Access Program will offer treatment for patients with ALS who have completed the phase 3 clinical trial and will not interfere with data or regulatory timelines.

Andrea Quattrone, MD, discusses how his team worked to create a simpler biomarker after developing MRPI 2.0.

Erenumab also demonstrated improvements in standard measures of efficacy, such as monthly migraine days.

UFC will provide $1 million contribution to fund research for a 5-year study that examines the effect of head impacts on long-term brain health.

The GW Pharmaceuticals product resulted in nearly 50% reductions in seizures at both 25 mg/kg and 50 mg/kg dose groups.

The director of the Montefiore Headache Center discussed how different treatments work for different patients with migraine.

The 3-part educational program is sponsored by Genentech.

Individuals whose mothers had pregestational diabetes mellitus had a statistically significant 2.3-fold increased risk of developing multiple sclerosis.